舒列安胶囊治疗前列腺增生（湿热下注证）的临床研究
|
摘要
目的:探讨舒列安胶囊治疗前列腺增生的临床疗效。
方法:选择62例前列腺增生患者,根据病历诊断、纳入、排除标准最后选择有效病例60例,其中治疗组30例,对照组30例。治疗组口服舒列安胶囊,每次2粒,每天3次;对照组口服翁沥通胶囊,每次3粒,每天2次。4周为1疗程,两组均治疗1疗程。对治疗前后临床症状、I-PSS、尿留率测定、残余尿量测定、前列腺体积测定等指标进行对照分析。
结果:治疗组总有效率为90%,对照组总有效率为70%,经Ridit分析(P＜0.05),两组疗效比较有显著差异.治疗组疗后临床症状、I-PSS、尿流率、残余尿量、前列腺体、中医症候积均有明显改善。
结论:舒列安胶囊治疗前列腺增生疗效显著,且疗效优于翁沥通胶囊。
Objective:To investigate the Shu Lie An Capsule treatment of benign prostatic hyperplasia clinical efficacy.
Methods:62 cases of patients with benign prostatic hyperplasia,according to medical diagnosis,inclusion,exclusion criteria final choice effective cases 60 cases,including 30 cases of the treatment group,the control group of 30 cases.KS treatment group oral capsules, each two,three times daily;control group Wen Li Tong capsules,each 3,2 times a day.Four weeks for a course of treatment,a course of treatment in both groups.Clinical symptoms before and after treatment,I-PSS,urine to stay rate determination of residual urine volume, prostate volume,and other indicators of controls.
Results:The total efficiency 90%for the control group,the total efficiency 70%,the PP analysis(P＜0.05),the effects were significant differences in the treatment group after therapy clinical symptoms,I-PSS,flow rate,residual urine volume,prostate volume has significantly improved.
Conclusion:KS capsules in treatment of benign prostatic hyperplasia significantly,And effective than Wen Li Tong capsules.
方法:选择62例前列腺增生患者,根据病历诊断、纳入、排除标准最后选择有效病例60例,其中治疗组30例,对照组30例。治疗组口服舒列安胶囊,每次2粒,每天3次;对照组口服翁沥通胶囊,每次3粒,每天2次。4周为1疗程,两组均治疗1疗程。对治疗前后临床症状、I-PSS、尿留率测定、残余尿量测定、前列腺体积测定等指标进行对照分析。
结果:治疗组总有效率为90%,对照组总有效率为70%,经Ridit分析(P＜0.05),两组疗效比较有显著差异.治疗组疗后临床症状、I-PSS、尿流率、残余尿量、前列腺体、中医症候积均有明显改善。
结论:舒列安胶囊治疗前列腺增生疗效显著,且疗效优于翁沥通胶囊。
Objective:To investigate the Shu Lie An Capsule treatment of benign prostatic hyperplasia clinical efficacy.
Methods:62 cases of patients with benign prostatic hyperplasia,according to medical diagnosis,inclusion,exclusion criteria final choice effective cases 60 cases,including 30 cases of the treatment group,the control group of 30 cases.KS treatment group oral capsules, each two,three times daily;control group Wen Li Tong capsules,each 3,2 times a day.Four weeks for a course of treatment,a course of treatment in both groups.Clinical symptoms before and after treatment,I-PSS,urine to stay rate determination of residual urine volume, prostate volume,and other indicators of controls.
Results:The total efficiency 90%for the control group,the total efficiency 70%,the PP analysis(P＜0.05),the effects were significant differences in the treatment group after therapy clinical symptoms,I-PSS,flow rate,residual urine volume,prostate volume has significantly improved.
Conclusion:KS capsules in treatment of benign prostatic hyperplasia significantly,And effective than Wen Li Tong capsules.
引文
[1]王永炎,山东科技出版 《泌尿外科学》 1993年版制定。
[2]伍阶平 裘法祖主编 《黄家驷外科学》 2004年3月六版
[3]Morrison AS:Risk factors for prostatic hypertrophy.Am.J.Epidemiol1992;135:974
[4]Choi J,Edward F,Benson MC.Cellular senescence:A novel mechanism in thedevelopment of BPH.J Urol,1999,161:Suppl 4,873.
[5]Riddle DL.Ageing.A message from the Gonads.Nature,1999,399:308-309.
[6]Hsin H,Kenyon C.Signals from the reproductive system regulate the life span of C.elegans.Nature,1999,399:362-366.
[7]Prehn RT.On the prevention and therapy of Prostate cancer by androgeadministration.Cancer Res,1999,59:4161-4164.
[8]鲍震美,细胞凋亡。中华泌尿外科杂志,1998.19:751-754.
[9]Green DR.Apoptotic pathway:the roads to ruin.Cell,1998,94:695-698.
[10]Kroerner G,Zamzami N,Susin SA.Mitochondria) control of apoptosis.(mmuno)Today,1997,18:44-51.
[11]Susin SA,Lorenzo HK,Zamzami N,et al.Molecular characterization ofmitochondrial apoptosis-inducing factor.Nature,1999,397:441-446.
[12]Tamm I,Wang Y,Sausville E,et al.IAP family protein surviving inhibitscaspase activity and apoptosis induced by Fas(CD95),Bax,caspase and;anticancer drugs.Cancer Res,1998,58:5315-5320.
[13]Deveraux QL,Takahashi R,Salvesen GS,et al.X - linked IAP is a directiinhibitor of cell-death protease.Nature,1997,388:300-304.
[14]Marcelli M,Cunning ham GR,Walkup M,et al.Signal pathway activatedduring apoptosis of the prostate cancer cell lone LNCaP:Over expression of Caspase 7 as a new gene therapy strategy for prostate cancer.Cancer Res,1999,59:382-390.
[15]Weinartner K,Ben Sasson SA,Stewart R,et al.Endothelial cell prolifer ationnactivity in BPH and prostate cancer,an in vitro model for assessment, J Urol, 1998, 159:465 - 470.
[16] Folkman J, Is tissue mass regulated by vascular endothelial cells?Prostate asthe first evidence. Endocrinology, 1998, 139:441-442.
[17] Nelson NJ. Angiogenesis research is on fast forward. J Natl Cancer Inst, 1999,91:820 -822.
[18] Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknownf eature of acromegaly. J Natl Cancer Inst, 1998,83:775-779.
[19] Price DT. New concepts in alpha-receptor biology. Office Education of 94thAnnual Meeting, AUA, 1999.
[20] Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosisby doaazosin in benign prostatic hyperplasia. J Urol, 1998, 159:1810-1815.
[21] Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasterideof both in benign prostatic hyperplasia. Veterans affairs cooperative studiesbenign prostatic hyperplasia study group. N Engl J Med, 1996,335:533 - 539.
[22] Hudson PB, Boake R, Trachtenberg J, et al. Efficiency of finasteride isimaintained in patients with BPH treated for 5 years. Urology, 1999, 53:690 - 695.
[23] Mc Connell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on thefrisk of acute urinary retention and the need for surgical treatment among men、 with benign prostatic hyperplasia. Finasteride Long - Term Efficacy and Safety: Study Group. N Engl J Med, 1998,338:557 - 563.
[24] Reddy PK, Wasserman NA, Berg P Zhang G, Kapoor DA:Patient selection (Predicts out - come following balloon dilatation of Prostate [abstract] , J Urol1991;145:362
[25] Reddy PK, Wasserman NA, Gfameda F, Casfaneda -Zuniga WR: Balloon dilatation of the Prostate for treatment of benign hyperplasia. Urol Clin North. Am 1998:15:529 - 535
[26] Kitagiwa M, Furuse H, Fukuta K, et al. Int J Urol, 1998;5(2):152 - 156
[27]Fabian KM:The intraprostatic partial catheter(Urologial spiral) in German.
[28]祁公任,陈涛,前列腺增生症中医病机证治观。江苏中医 1998,19(11):16
[29]任朴安,沈楚翘,治疗前列腺增生症经验。川中医药学报,1988,3(4):289
[30]周家珩,扶正化痰法治疗前列腺增生症135例。江苏中医 1991,12(3):115
[31]杜英博,冯老治疗老年病经验点滴实用。中医内科杂志 1992,6(4):184
[32]张惕君,对老年前列腺肥大防治的体会。中医杂志 1986,27(5):330
[33]吴光明,魏秋关,清热利湿化瘀法治疗前列腺肥大33例。湖南中医杂志,1993,9(3):36
[34]焦安钦,前列腺增生症病机特点与治疗思路。贵阳中医学院学报,1996,18(4):4
[35]何清湖,尿癃康对大鼠前列腺增生的影响。湖南中医药导报,1997,3(2-3):61
[36]余志红,复方前列宝抑制前列增生及抗炎作用的研究。数理医学杂志,1995,8(2):137
[37]彭培初,复方琥角片治疗前列腺增生症的临床实验研究。上海中医药杂志,1995,(1):1
[38]黄树刚,中药治疗前列腺肥大94例的性激素变化。南京中医学院学报,1994,10(2):10
[39]黄自强,金利油抑制前列腺增生及抗炎作用。中成药,1991,13(6):27
[40]杨文凯,前列宁对前列腺增生的影响及其抗炎作用的研究。中草药 1991,22(6):261
[41]宋杰云,消疬注射液的实验研究。中西医结合杂志,1990,(10):616
[42]方铁生,时永华.虚实分证论治前列腺增生症150例。南京中医药人学学报,1997,13(4)
[43]陈万年,从痰论证前列腺增生症57例。山东中医杂志,1995,14(10):446
[44]张文林,活血化瘀法治疗前列腺增生及急性尿潴留258例,辽宁中医杂志,1995,22(6):263
[45]石户则孝等,汉方最新治疗。1998:7(3):253-258
[46]关口由纪等,汉方最新治疗。1997:6(3):283-286
[47]马华,癃闭通治疗老年前列腺增生临床疗效观察。中医药研究,1996,(4):30
[48]陈志强,补肾祛淤疗法治疗前列腺增生症82例。新中医,1995,(2):19
[49]王劲松,自拟癃闭汤治疗前列腺增生症50例。国医论坛,1997,12(1):32
[50]张云程,中药治疗前列腺增生症90例。成都中医学院学报,1991,(3):16
[51]吴敬农,“补敛提汤”治疗老年前列腺肥大症64例。江苏中医,1996,17(1):17
[52]朱晓明,益气导水汤治疗前列腺增生症40例。湖南中医学院学报,1996,16(2):29
[53]牛宝生,前列舒煎治疗前列腺增生症68例。河南中医,1997,17(4):223
[54]张庆好,启癃汤治疗老年前列肥大55例。新中医,1995,27(2):23
[55]王敬善,前列丸治疗前列腺增生症和慢性前列腺炎81例。山东中医杂志,1990,9(6):12
[56]段登志,前列回春胶囊的药理作用和临床应用浅析。云南中医杂志,1995 16(1):5
[57]朱普英,州都丸治疗前列腺增生78例临床观察。河北中医,1992,14(6):8
[58]农方,金匮肾气丸治疗前列腺肥大10例。云南中医杂志,1994,15(5):13
[59]贾士安,胡遵达主任医师治疗前列腺增生经验。中医药研究,1995,(2):40
[60]罗振华,梁乃津教授治疗前列腺增生经验。新中医,1996,28(12):10
[61]李松林,启癃汤保留灌肠治疗前列腺增生尿渚留35例。陕西中医,1997,18(4):152
[62]李鸿林,中药水煎坐浴治疗前列腺增生症34例。实用中医药杂志,1995,(1):582
[63]王峻,中药熏治前列腺增生78例疗效观察。四川中医,1995(10)26
[64]林祖贤,三七粉治疗前列腺肥大。实用中西结合杂志,1994,(12):753
[65]王继贤,消痔灵局部注射治疗前列腺肥大。实用中医药杂志,1994,(3):39
[66]苗聘三,加味桂枝获荃丸治疗前列腺肥大引起的尿潴留。河南中医,1984(3),
[67]潘立群,试论前列腺增生症病机的确切含义。江苏中医药,2002,23(6):1-2
[68]张辉,当归四益汤加味治疗前列腺肥大42例。云南中医药杂志,1998,19(4):15
[69]刘松,龙胆桃夏汤治疗前列腺增生症34例。.湖北中医杂志 2003,25(2):39-39
[70]董自敏,癃闭开郁汤治疗前列腺肥大45例。四川中医,1995,13(12):27
[71]钟明平,加味滋肾丸治疗前列腺增生症50例。光明中医 2002,17(4):52-54
[72]晃中桓,中西医结合治前列腺肥大65例初步体会。中医杂志,1980,21(2):34
[73]艾长山,前列腺增生的中医证治。中国乡村医生杂志,2000,(2):35-36
[74]何红兵,从瘀辨证分型治疗老龄前列腺增生症72例。安徽中医临床杂志 2001,13(3):181
[75]许事位,辨证治疗老年性前列腺肥人20例。实用中医药杂志,2000,16(4):7
[76]王杰松,血管内皮细胞产生基质金属蛋白酶的作用与机制。国外医学·生理、病理科学与临床分册,2002,22(2):125-128
[77]曾仲,基质金属蛋白酶组织抑制剂的生物学功能。国外医学·分子生物学分册,2000, 22(2):84-87
[78]邓方明,夏同礼,顾方六,等.BPH组织中平滑肌成分的定量分析及意义。中华泌尿外科杂志,1994,12(5):297-298
[79]李建生,培元活血方治疗老年人前列腺增生症临床观察。中医研究,1994;7(2):24.
[80]张守福,自制补肾祛瘀通关丸治疗前列腺增生症90例。安徽中医临床杂志,1999;11(2):75.
[81]柯梦笔,前列平治疗前列腺增生症46例。山东中医杂志,1995;14(2):542.
[82]张蜀武,常德贵,张翠华等,通关胶囊治疗前列腺增生30例。成都中医药大学学报,1997;20(1):35.
[83]周淑英,邢军,张洪阳等,回春胶囊治疗前列腺增生症。山东中医杂志,1999;18(6):259.
[84]金正贤,消癃通闭汤治疗前列腺增生症63例临床观察。山东中医杂志,2000;19(7):403.
[85]王一庆,王惠兰,补肾化瘀散法治疗前列腺增生经验拾萃。新中医,2000;32(8):14.
[86]王永炎,王沛,今日中医外科.北京:人民卫生出版社,2000.666.
[2]伍阶平 裘法祖主编 《黄家驷外科学》 2004年3月六版
[3]Morrison AS:Risk factors for prostatic hypertrophy.Am.J.Epidemiol1992;135:974
[4]Choi J,Edward F,Benson MC.Cellular senescence:A novel mechanism in thedevelopment of BPH.J Urol,1999,161:Suppl 4,873.
[5]Riddle DL.Ageing.A message from the Gonads.Nature,1999,399:308-309.
[6]Hsin H,Kenyon C.Signals from the reproductive system regulate the life span of C.elegans.Nature,1999,399:362-366.
[7]Prehn RT.On the prevention and therapy of Prostate cancer by androgeadministration.Cancer Res,1999,59:4161-4164.
[8]鲍震美,细胞凋亡。中华泌尿外科杂志,1998.19:751-754.
[9]Green DR.Apoptotic pathway:the roads to ruin.Cell,1998,94:695-698.
[10]Kroerner G,Zamzami N,Susin SA.Mitochondria) control of apoptosis.(mmuno)Today,1997,18:44-51.
[11]Susin SA,Lorenzo HK,Zamzami N,et al.Molecular characterization ofmitochondrial apoptosis-inducing factor.Nature,1999,397:441-446.
[12]Tamm I,Wang Y,Sausville E,et al.IAP family protein surviving inhibitscaspase activity and apoptosis induced by Fas(CD95),Bax,caspase and;anticancer drugs.Cancer Res,1998,58:5315-5320.
[13]Deveraux QL,Takahashi R,Salvesen GS,et al.X - linked IAP is a directiinhibitor of cell-death protease.Nature,1997,388:300-304.
[14]Marcelli M,Cunning ham GR,Walkup M,et al.Signal pathway activatedduring apoptosis of the prostate cancer cell lone LNCaP:Over expression of Caspase 7 as a new gene therapy strategy for prostate cancer.Cancer Res,1999,59:382-390.
[15]Weinartner K,Ben Sasson SA,Stewart R,et al.Endothelial cell prolifer ationnactivity in BPH and prostate cancer,an in vitro model for assessment, J Urol, 1998, 159:465 - 470.
[16] Folkman J, Is tissue mass regulated by vascular endothelial cells?Prostate asthe first evidence. Endocrinology, 1998, 139:441-442.
[17] Nelson NJ. Angiogenesis research is on fast forward. J Natl Cancer Inst, 1999,91:820 -822.
[18] Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknownf eature of acromegaly. J Natl Cancer Inst, 1998,83:775-779.
[19] Price DT. New concepts in alpha-receptor biology. Office Education of 94thAnnual Meeting, AUA, 1999.
[20] Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosisby doaazosin in benign prostatic hyperplasia. J Urol, 1998, 159:1810-1815.
[21] Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasterideof both in benign prostatic hyperplasia. Veterans affairs cooperative studiesbenign prostatic hyperplasia study group. N Engl J Med, 1996,335:533 - 539.
[22] Hudson PB, Boake R, Trachtenberg J, et al. Efficiency of finasteride isimaintained in patients with BPH treated for 5 years. Urology, 1999, 53:690 - 695.
[23] Mc Connell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on thefrisk of acute urinary retention and the need for surgical treatment among men、 with benign prostatic hyperplasia. Finasteride Long - Term Efficacy and Safety: Study Group. N Engl J Med, 1998,338:557 - 563.
[24] Reddy PK, Wasserman NA, Berg P Zhang G, Kapoor DA:Patient selection (Predicts out - come following balloon dilatation of Prostate [abstract] , J Urol1991;145:362
[25] Reddy PK, Wasserman NA, Gfameda F, Casfaneda -Zuniga WR: Balloon dilatation of the Prostate for treatment of benign hyperplasia. Urol Clin North. Am 1998:15:529 - 535
[26] Kitagiwa M, Furuse H, Fukuta K, et al. Int J Urol, 1998;5(2):152 - 156
[27]Fabian KM:The intraprostatic partial catheter(Urologial spiral) in German.
[28]祁公任,陈涛,前列腺增生症中医病机证治观。江苏中医 1998,19(11):16
[29]任朴安,沈楚翘,治疗前列腺增生症经验。川中医药学报,1988,3(4):289
[30]周家珩,扶正化痰法治疗前列腺增生症135例。江苏中医 1991,12(3):115
[31]杜英博,冯老治疗老年病经验点滴实用。中医内科杂志 1992,6(4):184
[32]张惕君,对老年前列腺肥大防治的体会。中医杂志 1986,27(5):330
[33]吴光明,魏秋关,清热利湿化瘀法治疗前列腺肥大33例。湖南中医杂志,1993,9(3):36
[34]焦安钦,前列腺增生症病机特点与治疗思路。贵阳中医学院学报,1996,18(4):4
[35]何清湖,尿癃康对大鼠前列腺增生的影响。湖南中医药导报,1997,3(2-3):61
[36]余志红,复方前列宝抑制前列增生及抗炎作用的研究。数理医学杂志,1995,8(2):137
[37]彭培初,复方琥角片治疗前列腺增生症的临床实验研究。上海中医药杂志,1995,(1):1
[38]黄树刚,中药治疗前列腺肥大94例的性激素变化。南京中医学院学报,1994,10(2):10
[39]黄自强,金利油抑制前列腺增生及抗炎作用。中成药,1991,13(6):27
[40]杨文凯,前列宁对前列腺增生的影响及其抗炎作用的研究。中草药 1991,22(6):261
[41]宋杰云,消疬注射液的实验研究。中西医结合杂志,1990,(10):616
[42]方铁生,时永华.虚实分证论治前列腺增生症150例。南京中医药人学学报,1997,13(4)
[43]陈万年,从痰论证前列腺增生症57例。山东中医杂志,1995,14(10):446
[44]张文林,活血化瘀法治疗前列腺增生及急性尿潴留258例,辽宁中医杂志,1995,22(6):263
[45]石户则孝等,汉方最新治疗。1998:7(3):253-258
[46]关口由纪等,汉方最新治疗。1997:6(3):283-286
[47]马华,癃闭通治疗老年前列腺增生临床疗效观察。中医药研究,1996,(4):30
[48]陈志强,补肾祛淤疗法治疗前列腺增生症82例。新中医,1995,(2):19
[49]王劲松,自拟癃闭汤治疗前列腺增生症50例。国医论坛,1997,12(1):32
[50]张云程,中药治疗前列腺增生症90例。成都中医学院学报,1991,(3):16
[51]吴敬农,“补敛提汤”治疗老年前列腺肥大症64例。江苏中医,1996,17(1):17
[52]朱晓明,益气导水汤治疗前列腺增生症40例。湖南中医学院学报,1996,16(2):29
[53]牛宝生,前列舒煎治疗前列腺增生症68例。河南中医,1997,17(4):223
[54]张庆好,启癃汤治疗老年前列肥大55例。新中医,1995,27(2):23
[55]王敬善,前列丸治疗前列腺增生症和慢性前列腺炎81例。山东中医杂志,1990,9(6):12
[56]段登志,前列回春胶囊的药理作用和临床应用浅析。云南中医杂志,1995 16(1):5
[57]朱普英,州都丸治疗前列腺增生78例临床观察。河北中医,1992,14(6):8
[58]农方,金匮肾气丸治疗前列腺肥大10例。云南中医杂志,1994,15(5):13
[59]贾士安,胡遵达主任医师治疗前列腺增生经验。中医药研究,1995,(2):40
[60]罗振华,梁乃津教授治疗前列腺增生经验。新中医,1996,28(12):10
[61]李松林,启癃汤保留灌肠治疗前列腺增生尿渚留35例。陕西中医,1997,18(4):152
[62]李鸿林,中药水煎坐浴治疗前列腺增生症34例。实用中医药杂志,1995,(1):582
[63]王峻,中药熏治前列腺增生78例疗效观察。四川中医,1995(10)26
[64]林祖贤,三七粉治疗前列腺肥大。实用中西结合杂志,1994,(12):753
[65]王继贤,消痔灵局部注射治疗前列腺肥大。实用中医药杂志,1994,(3):39
[66]苗聘三,加味桂枝获荃丸治疗前列腺肥大引起的尿潴留。河南中医,1984(3),
[67]潘立群,试论前列腺增生症病机的确切含义。江苏中医药,2002,23(6):1-2
[68]张辉,当归四益汤加味治疗前列腺肥大42例。云南中医药杂志,1998,19(4):15
[69]刘松,龙胆桃夏汤治疗前列腺增生症34例。.湖北中医杂志 2003,25(2):39-39
[70]董自敏,癃闭开郁汤治疗前列腺肥大45例。四川中医,1995,13(12):27
[71]钟明平,加味滋肾丸治疗前列腺增生症50例。光明中医 2002,17(4):52-54
[72]晃中桓,中西医结合治前列腺肥大65例初步体会。中医杂志,1980,21(2):34
[73]艾长山,前列腺增生的中医证治。中国乡村医生杂志,2000,(2):35-36
[74]何红兵,从瘀辨证分型治疗老龄前列腺增生症72例。安徽中医临床杂志 2001,13(3):181
[75]许事位,辨证治疗老年性前列腺肥人20例。实用中医药杂志,2000,16(4):7
[76]王杰松,血管内皮细胞产生基质金属蛋白酶的作用与机制。国外医学·生理、病理科学与临床分册,2002,22(2):125-128
[77]曾仲,基质金属蛋白酶组织抑制剂的生物学功能。国外医学·分子生物学分册,2000, 22(2):84-87
[78]邓方明,夏同礼,顾方六,等.BPH组织中平滑肌成分的定量分析及意义。中华泌尿外科杂志,1994,12(5):297-298
[79]李建生,培元活血方治疗老年人前列腺增生症临床观察。中医研究,1994;7(2):24.
[80]张守福,自制补肾祛瘀通关丸治疗前列腺增生症90例。安徽中医临床杂志,1999;11(2):75.
[81]柯梦笔,前列平治疗前列腺增生症46例。山东中医杂志,1995;14(2):542.
[82]张蜀武,常德贵,张翠华等,通关胶囊治疗前列腺增生30例。成都中医药大学学报,1997;20(1):35.
[83]周淑英,邢军,张洪阳等,回春胶囊治疗前列腺增生症。山东中医杂志,1999;18(6):259.
[84]金正贤,消癃通闭汤治疗前列腺增生症63例临床观察。山东中医杂志,2000;19(7):403.
[85]王一庆,王惠兰,补肾化瘀散法治疗前列腺增生经验拾萃。新中医,2000;32(8):14.
[86]王永炎,王沛,今日中医外科.北京:人民卫生出版社,2000.666.